- Home
- BBDO vs MRNA Comparison
BBDO vs MRNA Comparison
Compare BBDO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBDO | MRNA |
|---|---|---|
| Founded | 1943 | 2010 |
| Country | Brazil | United States |
| Employees | 80348 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7B | 26.7B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BBDO | MRNA |
|---|---|---|
| Price | $2.98 | $79.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $34.27 |
| AVG Volume (30 Days) | 69.4K | ★ 8.0M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,263,000,000.00 |
| Revenue This Year | $70.86 | $9.36 |
| Revenue Next Year | $8.33 | $15.43 |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $2.37 | $22.28 |
| 52 Week High | $3.80 | $81.40 |
Technical Indicators
Market Signals| Indicator | BBDO | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.76 | 79.51 |
| Support Level | $2.85 | $45.69 |
| Resistance Level | $3.06 | N/A |
| Average True Range (ATR) | 0.11 | 5.44 |
| MACD | 0.02 | 2.06 |
| Stochastic Oscillator | 31.65 | 93.16 |
Price Performance
Historical ComparisonAbout BBDO Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.